

1 **Title page**

2 Outpatient and Home Pulmonary Rehabilitation Program Post COVID-19: A  
3 study protocol for clinical trial

4 **Short title:** Outpatient and Home Pulmonary Rehabilitation Program Post  
5 COVID-19

6 Luis V. F. Oliveira<sup>1\*</sup>¶, Miriã C. Oliveira<sup>1¶</sup>, Maria E. M. Lino<sup>2</sup>; Marilucia M. Carrijo<sup>1</sup>,  
7 João Pedro R. Afonso<sup>1</sup>, Ricardo S. Moura<sup>1</sup>, Adriano L. Fonseca<sup>1</sup>, Daniela R. P.  
8 Fonseca<sup>1</sup>, Luis Felipe R. J. Oliveira<sup>1</sup>, Letícia S. Galvão<sup>2</sup>, Bianca M. Reis<sup>2</sup>,  
9 Raphael H. C. O. Diniz<sup>2</sup>, Rubens R. Bernardes<sup>2</sup>, Elisângela R. P. Póvoa<sup>2</sup>,  
10 Anderson S. Silva<sup>3</sup>, Dante B. Santos<sup>1</sup>, Vinicius Z Maldaner<sup>1</sup>, Jean Carlos  
11 Coutinho<sup>1</sup>, Guilherme Pacheco Modesto<sup>1</sup>, Iransé Oliveira-Silva<sup>1</sup>, Rodrigo A. B.  
12 Lopes Martins<sup>1</sup>, Patrícia S. L. Lopes Martins<sup>1</sup>, Claudia S. Oliveira<sup>1</sup>, Gerson  
13 Cipriano Júnior<sup>1</sup>, Rodolfo P Vieira<sup>1</sup>, Renata K. Palma<sup>1,4</sup>, Larissa R. Alves<sup>1</sup>,  
14 Giuseppe Insalaco<sup>5</sup>.

15

16 <sup>1</sup>Human Movement and Rehabilitation Post Graduate Program, Evangelical  
17 University of Goiás – UniEVANGÉLICA, Anápolis (GO), Brazil.

18 <sup>2</sup>Scientific Initiation Program, Evangelical University of Goiás -  
19 UniEVANGÉLICA. Anápolis (GO), Brazil

20 <sup>3</sup>Health Sciences Post Graduate Program, Faculty of Medical Sciences, Santa  
21 Casa de São Paulo, São Paulo (SP), Brazil.

22 <sup>4</sup>Facultad de Ciencias Experimentales. Universidad Francisco de Vitoria,  
23 Madrid, Spain.

24 <sup>5</sup>Institute for Biomedical Research and Innovation, National Research Council -  
25 CNR, Palermo (SI), Italy.

26

27 **\*Corresponding author**

28 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.  
e-mail: [oliveira.lvf@gmail.com](mailto:oliveira.lvf@gmail.com) (LVFO)

## 29 **Funding**

30 This study protocol was approved in an emergency public call from the  
31 government of the State of Goiás (Brazil): Public Call: 06/2020 - Mapping of  
32 Proposals to Address Covid-19. Administrative process no.: 202010267000277.  
33 Research project: "COVID-19 Outpatient and Home Pulmonary Rehabilitation  
34 Program" from the Goiás State Research Support Foundation - FAPEG, Brazil.  
35 The full name of the funder is: Fundação de Amparo a Pesquisa do Estado de  
36 Goiás – FAPEG, Goiania (GO), Brazil. Website: <http://www.fapeg.go.gov.br>.  
37 The authors thank Evangelical University of Goiás - UniEVANGÉLICA for the  
38 partial support to the development of this research. The funders had and will not  
39 have a role in the study design, data collection and analysis, decision to publish,  
40 or preparation of the manuscript. The funding letter has been attached as a  
41 supporting file.

42 ASS receives grants of Coordenação de Apoio ao Pessoal de Nível Superior  
43 (CAPES/PROSUP); JPRA and RSM receives grants of Fundação de Amparo a  
44 Pesquisa (FAPEG), Goiás (GO), Brazil; LVFO receive grants Research  
45 Productivity, modality PQ1D; process no. 312731/2018-3 of Conselho Nacional  
46 de Desenvolvimento Científico e Tecnológico (local acronym CNPq), Brazil.  
47 RPV receive grants Research Productivity, modality PQII; process no.  
48 313299/2018-8 of Conselho Nacional de Desenvolvimento Científico e  
49 Tecnológico (local acronym CNPq), Brazil. CSO receive grants Research  
50 Productivity, modality PQII; process no. 310904/2021-8 of Conselho Nacional  
51 de Desenvolvimento Científico e Tecnológico (local acronym CNPq), Brazil.  
52 RABLM receive grants Research Productivity, modality PQ1D; process no.  
53 309920/2019-1 of Conselho Nacional de Desenvolvimento Científico e  
54 Tecnológico (local acronym CNPq), Brazil. GCJ receive grants Research  
55 Productivity, modality PQII; process no. 315604/2021-2 of Conselho Nacional  
56 de Desenvolvimento Científico e Tecnológico (local acronym CNPq), Brazil. GI  
57 is a senior researcher at the Institute for Biomedical Research and Innovation,  
58 National Research Council - CNR, Palermo (SI), Italy.

59

60

## 61 **Competing interests**

62 The authors have declared that no competing interests exist.

## 63 **Data Availability Statement**

64 All relevant data from this study will be made available upon study completion.

## 65 **Abstract**

### 66 **Background**

67 The coronavirus disease 2019 (COVID-19) is a widespread, highly contagious  
68 inflammatory process that causes respiratory, physical and psychological  
69 dysfunction. COVID-19 mainly affects the respiratory system and evolves in the  
70 acute phase from mild cases with common symptoms, such as fever, cough,  
71 and fatigue, to the moderate-to-severe form, causing massive alveolar damage  
72 resulting in dyspnea and hypoxemia that can rapidly progress to pneumonia,  
73 and acute respiratory distress syndrome. The acute form usually causes severe  
74 pulmonary sequelae such as pulmonary fibrosis or progression to organ failure,  
75 leading to worsening metabolic dysfunction and/or death.

### 76 **Purpose**

77 To verify the effects of an outpatient and home pulmonary rehabilitation  
78 program (PRP) on clinical symptoms, pulmonary function, physical activity level,  
79 functional status, autonomic activity, peripheral muscle strength, static and  
80 functional balance, functional mobility, anxiety and depression, post-traumatic  
81 stress, health-related quality of life, and survival of patients with sequelae from  
82 COVID-19.

### 83 **Methods**

84 This study will be a cohort, parallel, two-arm multicentric study, to be carried out  
85 in three clinical centers, with blind evaluation, with 06 weeks of training and  
86 follow-up. This study was designed according to the recommendations of the  
87 CONSORT statement. To be involved in this clinical study, according to the  
88 inclusion criteria, women and men aged between 16 and 75 years affected by  
89 COVID-19. The proposed PRP is based on the guidelines recommended by the

90 Global Initiative for Chronic Obstructive Lung Disease and, consists of a  
91 combination of aerobic and muscle strengthening exercises, lasting six weeks,  
92 with a frequency of three times a week.

### 93 **Discussion**

94 In patients infected with COVID-19 with persistent symptoms and sequelae,  
95 PRP mainly seeks to improve dyspnea, relieve anxiety and depression, prevent,  
96 and reduce complications and/or dysfunctions, reduce morbidity and mortality,  
97 and improve health-related quality of life.

98 **Trial registration:** This study was registered at [clinicaltrials.gov](https://clinicaltrials.gov) (ID: COVID-19  
99 PULMONARY REHAB NCT04982042).

### 100 **Introduction**

101 The disease caused by coronavirus disease 2019 (COVID-19) is  
102 characterized by a widespread, highly contagious inflammatory process that  
103 causes respiratory, physical, and psychological dysfunction in patients.  
104 COVID19 emerged in December 2019 in Wuhan, Hubei province, China, and  
105 alarmingly spread worldwide, with the growth in the number of cases and  
106 deaths being considered a global outbreak with a dramatic impact. It was  
107 declared a pandemic by the World Health Organization (WHO) in March 2020  
108 [1].

109 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused  
110 by COVID-19, mainly affects the respiratory system and evolves in the acute  
111 phase from mild cases with common symptoms, such as fever, cough, and  
112 fatigue, to the moderate-to-severe form, causing massive alveolar damage  
113 resulting in dyspnea and hypoxemia that can rapidly progress to pneumonia,  
114 acute respiratory distress syndrome (ARDS), difficult-to-correct metabolic  
115 acidosis, and clotting disorders. The acute form of COVID-19 usually causes

116 severe pulmonary sequelae such as pulmonary fibrosis or progression to  
117 multiple organ failure, leading to worsening metabolic dysfunction and/or death  
118 [2-4]. Hospital admission rates for COVID-19 patients have been difficult to  
119 estimate because they depend on the prevalence of community testing and  
120 admission criteria, which vary between countries [5]. The WHO reported that  
121 patients with COVID-19 develop signs and symptoms after 5 to 6 days of  
122 infection, although asymptomatic cases range from 27% to 40% of cases, as  
123 indicated by pre-vaccination data [6]. The mean time interval from the onset of  
124 the first symptoms of dyspnea to hospitalization and ARDS has been 5 to 8  
125 days, respectively, and in this same period, the scientific literature estimates  
126 that 80% of cases were asymptomatic or mild, 15% severe, and 5% critical [7-  
127 9]. Elderly, immunosuppressed, and hypertensive people with underlying  
128 chronic heart or lung disease are at a greater risk of developing the severe form  
129 of COVID-19, requiring admission to an intensive care unit (ICU) and  
130 progressing to a worse prognosis [10,11].

131 In view of the broad-spectrum clinical manifestations associated with  
132 multi-organ involvement in patients infected with SARS-CoV-2, the main acute  
133 complications are scientifically well-delineated; however, late outcomes are still  
134 in the recognition phase [12]. Considering the potential medium- and long-term  
135 sequelae in COVID-19 survivors, several organizations, including the WHO and  
136 the International Severe Acute Respiratory and Emerging Infection Consortium  
137 (ISARIC) have joined forces in scientific protocols and in the development of  
138 international recommendations to identify and define the severity of persistent  
139 manifestations after ICU and/or outpatient hospitalization [13].

140           The most common complaints reported in scientific literature after  
141 COVID-19 are caused by physiological, immunological, and inflammatory  
142 changes in response to infection, either directly by the virus or indirectly by the  
143 patient's immune response [14,15]. The main complaints were dyspnea and  
144 persistent fatigue followed by acquired muscle weakness, pulmonary  
145 dysfunction, intolerance to moderate efforts, myalgia and arthralgia, post-  
146 traumatic stress disorder (PTSD), anxiety, and depression, which justify the  
147 worsening of functional status and quality of life in these patients [11,12,16,17].  
148 The fact that the frequency and severity of post-disease symptoms are not  
149 directly associated or are exclusive to patients in the risk group or who develop  
150 the severe form makes it an urgent need to characterize risk predictors and the  
151 potential differences between post-intensive care syndrome and the assignment  
152 of rehabilitation programs to minimize sequelae [18,19].

153           The scientific community and health professionals have discussed the  
154 challenge of rehabilitating these patients who present with an infinity of clinical  
155 manifestations, considering that knowledge is an important variable in  
156 formulating guidelines aimed at structuring the organization, clinical treatment,  
157 and pulmonary rehabilitation of these patients with a focus on the  
158 implementation of preventive and therapeutic measures [20-22]. The American  
159 Thoracic Society and European Respiratory Society (ATS/ERS) task force  
160 advocates the inclusion of COVID-19 survivors in a pulmonary rehabilitation  
161 program (PRP) lasting 6–8 weeks. The initial experience in China also indicates  
162 that a 6-week program can improve lung function, quality of life variables,  
163 anxiety, and depression [23,24].

164 Pulmonary rehabilitation is defined as "a multidisciplinary intervention  
165 based on personalized assessment and treatment, which includes exercise  
166 training, education, and behavioral modification designed to improve the  
167 physical and psychological condition of people with respiratory disease" [25]. In  
168 patients infected with COVID-19 with persistent symptoms and sequelae,  
169 pulmonary rehabilitation mainly seeks to improve dyspnea, relieve anxiety and  
170 depression, prevent and reduce complications and/or dysfunctions, reduce  
171 morbidity and mortality, and improve health-related quality of life as much as  
172 possible [26,27].

173 Aerobic exercises, training of the ventilatory muscles, and muscle  
174 strengthening of the lower and upper limbs should be progressively offered to  
175 patients so that they can gradually recover the level of physical activity  
176 observed before the onset of the disease and eventually return to normal  
177 activities of daily living (ADLs). The principle of personalization must be  
178 respected regardless of the type of intervention in a PRP, based on the specific  
179 dysfunction of each patient [28-30].

## 180 **Objectives**

181 To verify through a clinical, prospective, and consecutive study the  
182 effects of an outpatient and home pulmonary rehabilitation program on clinical  
183 symptoms, pulmonary function, physical activity level, functional status,  
184 autonomic activity, peripheral muscle strength, static and functional balance  
185 assessment, functional mobility, anxiety and depression, post-traumatic stress,  
186 quality of life, and survival of patients with pulmonary sequelae from COVID-19.

187

## 188 **Materials and Methods**

### 189 **Study design**

190 This study will be a cohort, parallel, two-arm multicentric study, to be carried out  
191 in three clinical centers, with blind transversal and longitudinal evaluation, with  
192 06 weeks of training and follow-up. This clinical trial was designed according to  
193 the recommendations of the CONSORT statement [31]. This study protocol has  
194 been designed in accordance with the SPIRIT 2013 Guidelines [32]. Currently,  
195 this clinical trial is recruiting patients. The schedule of enrollment, interventions,  
196 and assessments according to the SPIRIT guidelines are shown in Figure 1. All  
197 procedures of the study adhere to the CONSORT guidelines and are  
198 summarized in a flowchart (Figure 2).

199 **Figure 1.** Schedule of enrollment, interventions, and assessments from SPIRIT  
200 guidelines.

201 **Figure 2.** Study flowchart in accordance with the CONSORT statement.

202

### 203 **Study setting**

204 The study will be conducted at the Pulmonary Rehabilitation Laboratory of the  
205 Evangelical University of Goiás, UniEVANGÉLICA. Recruitment will take place  
206 between July 2021 and December 2022 through social media and banners  
207 distributed in reference hospitals for the treatment of patients with COVID-19 in  
208 the city of Anápolis (GO), Brazil. The city of Anápolis, in the interior of the state  
209 of Goiás, in the Midwest region of Brazil, is considered a center of reference in  
210 health in the region, receiving patients from several surrounding municipalities.



211 Many patients who seek care in the city come from neighboring cities and  
212 therefore do not have an assistance service in the field of pulmonary  
213 rehabilitation, and international biosafety standards for protection against  
214 COVID-19 will be observed.

#### 215 **Ethical considerations and consent to participate**

216 All procedures performed with the patients involved in this study were in  
217 accordance with the international ethical standards for research involving  
218 human. The research protocol was approved by the Ethics Committee for  
219 Research with Human Beings of Universidade Evangélica de Goiás  
220 (UNIEVANGÉLICA) on September 24, 2020, under protocol number 4,235,203.  
221 This clinical trial was registered at ClinicalTrials.gov (ID: COVID-19  
222 PULMONARY REHAB NCT04982042). Involvement in the study will be  
223 voluntary, and leave will be allowed at any time without any burden. Participants  
224 will be required to sign an informed consent form after receiving all information  
225 about the pulmonary rehabilitation program.

#### 226 **Participants: recruitment and eligibility criteria**

227 To be involved in this clinical study, according to the inclusion criteria, women  
228 and men aged between 16 and 75 years affected by COVID-19 will be invited.

#### 229 **Inclusion criteria**

230 The following are the inclusion criteria:

231 Age 16–75 years

232 Patients who have been affected by COVID-19 and with impaired lung function

233 Clinically stabilized patients

234 Patients who agreed to participate in the pulmonary rehabilitation program for at  
235 least 12 weeks and signed a free and informed consent form

236 **Exclusion criteria**

237 The following are the exclusion criteria:

238 Hospitalized patients

239 Patients affected with chronic neurological diseases that make it impossible to  
240 understand and perform physical activities

241 Patients suffering from hypertension and cardiovascular conditions without  
242 medical treatment

243 Patients affected with acute phase of rheumatologic disorders

244 Patients who have recent musculoskeletal disorders and who are not fully  
245 recovered from their injuries

246 Patients affected with chronic mental and/or psychological disturbances

247 Presence of terminal neoplastic disease

248 Red flags for serious conditions (night pain, severe muscle spasm, loss of  
249 involuntary weight, and symptom mismatch)

250 Patients classified as severe cases according to the following criteria will also  
251 be excluded.

252 • Respiratory rate  $\geq$  30 rpm

253 • SpO<sub>2</sub> < 90%

- 254 • Cardiac rate > 125 bpm
- 255 • Hypotension (systolic blood pressure < 90 mmHg or diastolic blood  
256 pressure < 60 mmHg)
- 257 • Severe dyspnea (minimal effort or rest)
- 258 • Hemoptysis
- 259 • Altered alertness (lethargy, acute confusion, disorientation)
- 260 • Inability to consume orally due to unintended vomiting or a significant  
261 number of bowel movements ( $\geq 10$  per day), suggesting dehydration or  
262 hydroelectric disturbances
- 263 • Significant impact on general health condition
- 264 • A high clinical suspicion of pneumonia requiring radiography, based on  
265 worsening of dyspnea, more than 7 days with fever, respiratory rate  
266 higher than 22 rpm, and alteration in auscultation findings.

## 267 **Interventions**

268 Initially, all patients who met the inclusion criteria underwent clinical, physical,  
269 and psychological evaluations. They will then perform pulmonary function tests  
270 [33], peripheral muscle strength tests [34], and the 6-min walk test (6 MWT), in  
271 accordance with the standards recommended by the ATS [35]. The modified  
272 dyspnea scale of the Modified Medical Research Council [36] and the scales for  
273 anxiety and depression [37] will also be applied.

274 The proposed outpatient PRP is based on the guidelines recommended by the  
275 Brazilian Society of Pulmonology [38] and by the Global Initiative for Chronic  
276 Obstructive Lung Disease [39]. The Outpatient Pulmonary Rehabilitation  
277 Program consists of a combination of aerobic and muscle strengthening

278 exercises, lasting six weeks, with a frequency of three times a week, every  
 279 morning, according Table1. The pulmonary rehabilitation program consists of  
 280 warm-up, training, and cool-down phases. The warm-up phase consisted of  
 281 intercalated calisthenic exercises for the muscle groups of the lower and upper  
 282 limbs according to each patient's tolerance. The aerobic training phase is  
 283 performed on a treadmill or bicycle according to the patient's preference. During  
 284 the cooling-down phase, muscle stretching, and relaxation exercises are  
 285 performed in a calm and silent environment.

286 **Table 1.** Combined aerobic exercise and muscle strengthening exercises  
 287 training periodization.

288

	Outpatient PRP		Home PRP	
	Week 1-3	Week 4-6	Week 1-3	Week 4-6
	Sets x Repetitions	Sets x Repetitions	Sets x Repetitions	Sets x Repetitions
<b>Aerobic exercise</b>				
Bicycle/treadmill or walking				
Volume	30 minutes	40 minutes	30 minutes	40 minutes
Intensity, % HR 6MWT	60-70% (4-5 RPE)	70-80% (5-6 RPE)	50-60% (4-5 RPE)	60-70% (5-6 RPE)
<b>Muscle strengthening exercises</b>				
Upper limb				
Upper limb diagonal (D1, adapted kabat)	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15
Upper limb diagonal (D2, adapted kabat)	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15
Lower limb				

Hip flexors with extended knee	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15
knee extenders	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15
knee flexors	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15
plantar flexors	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15
Volume	20 minutes	30 minutes	20 minutes	30 minutes
Intensity, % 1RM	50-60% (4-5 RPE)	60-70% (5-6 RPE)	50-60% (4-5 RPE)	60-70% (5-6 RPE)

289 PRP: Pulmonary Rehabilitation Program; HR heart rate; 6MWT: Six Minute  
 290 Walk Test; RPE: rating of perceived exertion; 1RM: one repetition maximum  
 291 test;

## 292 **Home PRP**

293 Home PRP will consist of the same combination of warm-up, strengthening,  
 294 training, and relaxation exercises as the outpatient PRP. Initially, patients in this  
 295 group will receive exercise program training by a specialized healthcare  
 296 professional on the research team and will be encouraged to follow the protocol  
 297 at home. The aerobic conditioning of this group will be performed by walking on  
 298 a flat terrain for up to 20 min, with an intensity of 60% to 80% of the maximum  
 299 heart rate reached in the 6 MWT, respecting individual tolerance and self-  
 300 monitoring throughout the training. You will be asked to complete a diary for  
 301 each training session. During the 6 weeks of training, individuals will receive  
 302 weekly phone calls from the same researcher on the team to monitor the load  
 303 increase, detect any type of problem, clarify possible doubts, and reinforce the  
 304 importance of rehabilitation. Patients will be recommended to decrease the  
 305 intensity or discontinue the exercise in case of a high degree of dyspnea or any  
 306 other symptom of discomfort. The criteria for load increment in the upper- and  
 307 lower-limb exercises will be the same as those for the outpatient group.

308 Upon completing 6 weeks of activities in the pulmonary rehabilitation program,  
309 patients will be recruited for a new evaluation, discharged, and encouraged to  
310 continue physical activities inherent to PRP at home. Each month, a new  
311 telephone contact will be made by a blinded evaluator asking about the general  
312 health status, adverse effects, and guidance regarding the continuity of physical  
313 activities.

#### 314 **Outcomes and measurements**

315 All data regarding the initial and final evaluations after 6 weeks of training will be  
316 collected by two physiotherapist researchers from the team. The collected data  
317 will be registered in standard forms for each outcome and then entered into an  
318 Excel database for further analysis. Pulmonary function tests will be performed  
319 by a technician trained in pulmonary function and interpreted by a  
320 pulmonologist. Physical therapists will perform muscle strength and exercise  
321 capacity tests. Quality of life questionnaires and anxiety, depression, and stress  
322 scales will be administered by an expert psychologist. All physical activities in  
323 the PRP will be monitored by two physiotherapists, who will continuously check  
324 the patients' vital signs. Below, we present the outcomes that will be evaluated  
325 in the baseline evaluation and after 6 weeks of participation in the program. The  
326 outcomes, measures, and assessment methods adopted in this clinical trial are  
327 shown in Table 2.

328 **Table 2.** Outcomes, measures, and assessment methods that will be used in  
329 this clinical trial.

OUTCOMES	MEASURES	ASSESSMENT	
		t1	t2
Pulmonary Function (FVC, VEF <sub>1</sub> ,	Spirometry test	X	X

VEF <sub>1</sub> / FVC)			
Exercise Capacity	6MWT	X	X
Status Funcional	Post-COVID-19 Functional Status Scale	X	X
Severity of Dyspnea	MRC Dyspnea Scale	X	X
Data on physical and, psychosocial health and pre-COVID-19 baseline data	ISARIC Global Tier 1 COVID-19 Follow Up Survey. v1.2 21 Jan. 2021	X	X
Maximal Inspiratory Pressure	POWERbreath	X	X
Sympathetic and Parasympathetic Autonomic Activity	Heart Rate Variability Analyses	X	X
Peripheral Muscle Strength	Handgrip dynamometer	X	X
	MRC-SS	X	X
Static Balance Assessment	Force Platform	X	X
Functional Balance Assessment	Berg Balance Scale	X	X
Functional Mobility	TUG test	X	X
Muscle Fatigue	FSS	X	X
Quality of Life	SF-36 Questionnaire	X	X
	EQ-5D-5L	X	X
Anxiety and Depression Levels	HADS	X	X
	SAS/SDS	X	X
Posttraumatic Stress Disorder	IES-6	X	X

330 t1: before intervention; t2: after intervention; FVC: Forced vital capacity; VEF<sub>1</sub>:  
331 Forced expiratory volume in one second; 6MWT: Six Minute Walk Test; mMRC:  
332 modified Medical Research Council; ISARIC: International Severe Acute  
333 Respiratory and emerging Infection Consortium; MRC-SS: Medical Research  
334 Council Sum-Score; TUG: Timed Up and Go; FSS: Fatigue Severity Scale; SF-  
335 36: Short Form-36; EQ-5D-5L: EuroQol five dimension five levels; HADS:  
336 Hospital Anxiety and Depression Scale; SAS/SDS: The Self-Assessment of  
337 Anxiety Scale and the Self-Assessment of Depression Scale; IES-6: Event  
338 Impact Scale - 6.

339

340 **Primary outcome**

341 **Pulmonary function: spirometry test**

342 The Koko Sx 1000 spirometer (Koko PFT, Fordham, Longmont, CO, USA) will  
343 be used according the guidelines of the ERS, ATS [40, 41], and Brazilian  
344 Society of Pneumology [42]. Spirometry tests will be performed on all patients in  
345 the morning after two puffs of salbutamol (400 µg), which will be administered  
346 using a spacer (Volumatic, Glaxo Smith Kline LTD, London, UK). The best  
347 forced expiratory volume in one second (FEV1) and forced vital capacity (FVC)  
348 were chosen for all analyses, regardless of the best curve. The ATS/ERS  
349 acceptability criteria for spirometry will be applied, including a minimum of three  
350 respiratory maneuvers with at least two being free from artifacts.

351 **Exercise capacity: walk test (6 MWT)**

352 According to the guidelines published by the ATS (2002), the 6 MWT  
353 evaluates the distance a patient can walk quickly for a maximum period of 6  
354 MWD. This test assesses the global and integrated responses of all systems  
355 involved in physical activities. [43] The 6 MWT is a simple, reliable, practical,  
356 low-cost, safe, and easy-to-apply functional capacity measure that can be  
357 performed in a flat, rigid space of 30 m. [44-46]

358 The test has been widely used to assess the functional status of patients  
359 with cardiorespiratory impairment and is highly correlated with morbidity and  
360 mortality [47-51]. An interesting review concluded that the 6 MWT is easy to  
361 administer, better tolerated, and more representative of ADLs than other  
362 walking tests [52].

363



364 **Status Functional status: Post COVID-19 Functional Status Scale (PCFS)**

365 Due to the wide variety of clinical symptoms and sequelae presented by  
366 patients after COVID-19, it is of great importance to have a simple and  
367 reproducible tool to assess the impact of the disease, monitor its evolution, and  
368 guide rehabilitation actions [53,54]. Given the high incidence of pulmonary  
369 embolism with myocardial damage/myocarditis and neurological complications  
370 in patients with critical-stage COVID-19, Dr. Klok et al. proposed the use of the  
371 PVFS scale (with a small adaptation) in the evaluation of patients after COVID-  
372 19. The authors suggest the use of the PVFS scale at hospital discharge, 4 and  
373 8 weeks after discharge, and 6 months to assess the recovery of these patients.  
374 They also recognized that this instrument should not replace other established  
375 and validated instruments in the assessment of quality of life, tiredness, or  
376 dyspnea but could also be used as a tool for evaluating the results of the  
377 functional state of intervention actions after COVID-19 [55,56].

378 This instrument covers functional level, limitations in daily life tasks, and lifestyle  
379 changes at six levels. Level 0 demonstrates the absence of any functional  
380 limitation, and the death of a patient is recorded in grade D. From level 1  
381 onwards, symptoms, pain, or anxiety are presented in ascending order. This  
382 had no effect on the activities of patients in grade 1, whereas a lower intensity  
383 of activities was required for those in grade 2. Level 3 is characterized by the  
384 inability to perform certain activities, forcing patients to adapt. Finally, level 4 is  
385 reserved for patients with severe functional limitations who need assistance in  
386 performing ADLs [57, 58].

387

## 388 **Severity of dyspnea: Medical Research Council (MRC) Dyspnea Scale**

389 In patients with chronic obstructive pulmonary disease (COPD), it has been  
390 observed that the interaction between dyspnea, physical deconditioning, and  
391 muscle weakness results in a vicious circle or negative spiral [59], which  
392 generates important functional limitations [60]. In real life, these functional  
393 limitations are characterized by a reduction in the ability to perform ADLs [61]. It  
394 has been observed that a close relationship exists between physical ADL,  
395 morbidity, and mortality in patients with COPD, calling attention to the adequate  
396 evaluation and follow-up of their evolution [62-64]. In this study, owing to its  
397 ease of application and understanding, the MRC scale will be used, an  
398 instrument traditionally used in the international literature [65,66].

399 The MRC scale consists of five items, where the patient defines the item that  
400 best corresponds to the extent to which dyspnea limits daily activities. The  
401 patient reported his subjective degree of dyspnea, choosing a value between 1  
402 (shortness of breath only during intense exercise) and 5 (shortness of breath  
403 when getting dressed or feeling short of breath that he no longer leaves the  
404 house) [67,68].

## 405 **Secondary outcome**

### 406 **Physical and psychosocial health COVID-19: International Severe Acute** 407 **Respiratory and Emerging Infections Consortium (ISARIC)**

408 ISARIC has recently published the COVID-19 response timeline to mark the  
409 amazing work performed by all those using ISARIC's resources and clinical  
410 data platform since the beginning of the pandemic; the timeline showcases how  
411 the federation has taken action right from the start of the pandemic to address

412 the most important research questions to further the knowledge of COVID-19,  
413 thereby saving lives and providing a collaborative platform through which global,  
414 patient-oriented clinical studies can be developed, executed, and shared.

415 Protocols addressing the most important questions between and during  
416 epidemics of severe acute respiratory infections and other rapidly emerging  
417 public health threats are undertaken to generate new knowledge, maximize the  
418 availability of clinical information, and thereby save lives.

419 The ISARIC COVID-19 follow-up protocol was based on the ISARIC/WHO  
420 COVID-19 Clinical Characterization Protocol. It assesses the risk and risk  
421 factors for long-term physical and psychosocial health consequences following  
422 COVID-19 diagnosis using a range of validated tools. This protocol will follow-  
423 up patients with confirmed COVID-19 using standardized data collection forms.

424 The forms can be completed as patient self-assessment via post or an online  
425 link, or via clinician/research-led completion via telephone or in-clinic. It can be  
426 used to identify people for further in-clinic follow-up and assessment or in  
427 conjunction with sampling and diagnostic studies.

428 Assessment of the risk factors for long-term sequelae requires data on pre-  
429 existing conditions and care received during the acute phase of the disease. In  
430 this way, ISARIC created tools for researchers to collect and store clinical data  
431 in a standardized manner through COVID-19 follow-up surveys. The Tier 1  
432 Initial Follow-up Survey will be used in the initial assessment of patients, and  
433 the Tier 1 Ongoing Follow-up Survey will be used in the reassessment after six  
434 weeks of intervention. The original versions were made available in English and  
435 were later translated into other languages, including Portuguese [69,70].

436 This is an open-access tool that collects data on physical and  
437 psychosocial health, occupational status, and socioeconomic variables, as well  
438 as pre-COVID-19 baseline data that make it possible to characterize the  
439 physical and psychosocial repercussions after hospital discharge and/or sharp.  
440 These include vaccination data, hospitalization and possible decompensations  
441 and/or readmissions, specific consequences including deep vein thrombosis  
442 (DVT), stroke or transient ischemic attack, pulmonary embolism, recent febrile  
443 illness, new or persistent symptoms, quality of life (assessed using the EQ-5D-  
444 5L and EQ VAS), dyspnea (measured by the MRC dyspnea scale), difficulties in  
445 ADLs due to health problems (UN/Washington disability score), and lifestyle  
446 [71].

#### 447 **Maximal inspiratory pressure (MIP): POWERbreath**

448 The pressure generated by the inspiratory muscles will be quantified  
449 using an electronic threshold device (PowerBreathe Medic KH2, IMT  
450 Technologies Ltd., Birmingham, UK). It features an advanced live feedback  
451 software (Breathe-Link Medic), which allows patient results to be viewed in real  
452 time. To measure the MIP, patients should be comfortably seated, encouraged  
453 to perform a maximal expiratory effort from the residual volume, and then a  
454 verbal command will be given to perform a maximal inspiratory effort, according  
455 to ATS/ERS standards [72]. The reference values used were described by  
456 Pessoa et al. (2014), based on parameters for the Brazilian population [73].

#### 457 **Nervous autonomic activity: heart rate variability (HRV) analyses**

458 HRV was analyzed using Kubios HRV software (Kubios Ou Limited company,  
459 Kuopio, Finland). This software is widely known and is used worldwide with

460 different patient populations and healthy individuals. It is a well-developed,  
461 validated, and easy-to-use software for analyzing the behavior of sympathetic  
462 and parasympathetic autonomic activities. This software is considered to be the  
463 gold standard for HRV analysis. In this clinical research protocol, HRV analysis  
464 will be performed during the 6 MWT. Data will be collected using the Kubios  
465 software from the heart rate and time, obtaining the time values referring to the  
466 R-R intervals. Five minutes will be collected with the patient seated, at rest  
467 before starting the test, during the 6 min of walking and for 5 min after the test,  
468 and sitting at rest. HRV analyses will be performed in the time and frequency  
469 domains, as well as in nonlinear models.

#### 470 **Peripheral muscle strength**

##### 471 **Handgrip dynamometer**

472 According to the recommendations of the American Society of Hand Therapists,  
473 handgrip strength should be assessed using a dynamometer on both sides  
474 (dominant and non-dominant). In this protocol, hand grip strength will be verified  
475 using the digital hand dynamometer Jamar® Plus Hand Dynamometer  
476 (JAMAR® Hydraulic Hand Dynamometer, Sammons Preston, Bolingbrook, IL,  
477 USA). Patients should be seated with their feet firmly on the floor, shoulders  
478 adducted, elbows flexed at 90°, and forearms in a neutral position [74], and the  
479 position of the equipment handle should be chosen by the patient himself [75].  
480 Three tests will be performed on each side, alternately, with a rest period of at  
481 least 1 min between attempts on the same hand [76]. The highest value  
482 observed in each upper limb was used to represent maximum handgrip strength  
483 [77]. The dynamometer was adjusted according to the size of the hand of each

484 patient. After instruction, the participant pressed the dynamometer until  
485 maximum strength was displayed, and the results were recorded in kilograms to  
486 one decimal place [78].

#### 487 **MRC sum-score (MRC-SS)**

488 The MRC-SS assesses the global peripheral muscle strength of six upper and  
489 lower limb muscle groups (shoulder abduction, elbow flexion, wrist extension,  
490 hip flexion, knee extension, and ankle dorsiflexion) on both sides, from 5  
491 (normal strength) to 0 (no visible contraction). The sum of the scores ranges  
492 from 0 to 60, where scores below 48 indicate significant peripheral muscle  
493 weakness and scores below 36 indicate severe weakness. The therapist's hand  
494 placement and patient positioning were standardized [79].

495 Muscle strength will initially be evaluated against gravity, and the movements to  
496 be evaluated will be passively demonstrated. If the patient could not perform the  
497 movement, positioning was modified [80]. An isometric resistance was applied  
498 to the end of the range of motion to test each degree of muscle strength. This  
499 score has been widely used for the diagnosis of ICU-acquired weakness (ICU-  
500 AW) [81,82].

#### 501 **Functional balance assessment: Berg balance scale**

502 The Berg balance scale assesses functional balance by performing 14  
503 tasks of daily living, with a global score of 56 possible points. Items were scored  
504 from 0-4, with 0 representing the inability to complete the task and 4  
505 representing the ability to complete the proposed task. A score from 0 to 20  
506 represents impairment of balance, 21 to 40 represents acceptable balance, and  
507 41 to 56 represents good balance [83].

508

509 **Functional mobility: timed Up & Go (TUG)**

510 The TUG test is an instrument that allows the assessment of functional mobility  
511 in different populations as a function of time [84,85]. To perform the test, the  
512 patient had to get up from a standardized chair, walk 3 m at a comfortable pace,  
513 return to the chair, and sit down. The test will be performed with the subjects on  
514 barefoot/shoes three times, the first time for familiarization. Time intervals  
515 above 16 s are indicate impairment of the patient's functional mobility and  
516 identified as a high fall risk [86].

517 TUG test data were obtained using a wireless inertial detection device: Inertial  
518 Sensor: G-Sensor® (BTS Bioengineering Corp., Quincy, MA, USA). A portable  
519 Gsensor is a wireless inertial sensor system used to analyze human  
520 movements. The sensors were controlled by a data logging unit (up to 16  
521 elements) via ZigBee-type radio communication. Each sensor has dimensions  
522 of 62 mm × 36 mm × 16 mm, weighs 60 g, and is composed of a three-axis  
523 accelerometer (maximum scale ± 6 g), a 3-axis gyroscope (full scale ± 300°/s),  
524 and a magnetometer 3-axis (full scale ± 6 Gauss). This device was calibrated  
525 with gravitational acceleration immediately after manufacturing. For this study,  
526 only one device was used to collect data at a sampling frequency of 50 Hz. The  
527 data from the inertial sensor were transmitted via Bluetooth to a computer and  
528 processed using proprietary software (BTS GSTUDIO, version: 2.6.12.0), which  
529 automatically provided the parameters. The TUG test has been validated in a  
530 population of patients with COPD.

531

## 532 **Static balance assessment: Force platform**

533 Postural balance is assessed using stabilometry, also called oscillometry, which  
534 measures oscillations in the standing posture. This condition is measured  
535 through the displacement of the center of pressure (COP) while the individual  
536 remains standing on the platform for a certain time [87]. It allows detection of  
537 the slightest variations in amplitude and frequency of displacement of the body's  
538 center of gravity, helping to analyze the functional aspects related to body  
539 imbalance. It is a technique used to evaluate the plantar pressure exerted by  
540 the body, which allows the detection of postural oscillations and balance deficits  
541 [88].

542 To assess static balance, the SMART-D 140® System (BTS Bioengineering  
543 Corp., Quincy, MA, USA) containing two force platforms (Kistler Platform model  
544 9286BA) was used. The platform acquisition frequency was 100 Hz, captured  
545 by four piezoelectric sensors positioned at the extremities of the force platform  
546 measuring 400/600 mm. Data were recorded and interpreted using SWAY BTS  
547 161 Engineering software (BTS Bioengineering Corp., Quincy, MA, USA),  
548 integrated, and synchronized with the SMART-D 140® system (BTS  
549 Bioengineering Corp., Quincy, MA, USA). The collection protocol to be  
550 conducted includes the instruction to remain in a standing position, as still as  
551 possible, with the arms close to the body and the head kept in a vertical  
552 position. Measurements (30 s) of the COP displacement on the X (anterior-  
553 posterior), Y (medium-lateral), and COP-GOG axes will be taken under the  
554 conditions of eyes open and eyes closed, with the proprioceptive perturbation  
555 that configures as a soft surface collecting with open eyes and eyes closed.



556 **Muscle fatigue: Fatigue Severity Scale (FSS)**

557 The FSS is one of the most widely used fatigue self-assessment scales  
558 worldwide. This scale classifies the severity of a patient's fatigue symptoms in  
559 terms of how they compromise their motivation, physical activity, and ADLs. The  
560 scale is composed of a self-report questionnaire with nine items, with scores  
561 ranging from 1 to 7, where 1 indicates strongly disagree and 7 indicates strongly  
562 agree [89,90]. The scale is scored by the total sum or by the calculation of an  
563 average score on the nine items, with higher scores indicating more severe  
564 fatigue. A score  $\geq 4$  indicated fatigue [91]. The FSS has been translated and  
565 validated in several languages including Portuguese. Participants will be asked  
566 to respond to the FSS relative to the previous week [92].

567 **Health-related Quality of life**

568 **Short Form Health Survey 36 (SF-36) questionnaire**

569 In this protocol, health-related quality of life is assessed using a generic  
570 instrument. The SF-36 is a multidimensional questionnaire frequently used to  
571 assess the quality of life of patients. This instrument was developed by Ware  
572 and Sherbourne [93] and validated in Brazil by Ciconelli et al. [94]. It consists of  
573 36 questions that analyze eight health domains: functional capacity, limitations  
574 due to physical aspects, pain, general health status, vitality, social aspects,  
575 limitations due to social aspects, and mental health [95]. A final score ranging  
576 from 0 to 100 is generated from each domain, and the higher the score, the  
577 better the health-related quality of life [96].

578

## 579 **EuroQol five dimension five levels (EQ-5D-5L)**

580 The EQ-5D-5L version was introduced by the EuroQol Group in 2009 with the  
581 aim of improving the instrument's reliability and sensitivity compared to the EQ-  
582 5D-3L. The EQ-5D-5L consists of the EQ-5D descriptive system, covering five  
583 dimensions: mobility, self-care, usual activities, pain/discomfort, and  
584 anxiety/depression. Each dimension has five levels of severity: none, mild,  
585 moderate, severe, and extreme. The patients will be asked to indicate their  
586 health status in each of the five dimensions. A score can be calculated from the  
587 scores generated by each domain, with higher scores representing a better  
588 quality of life [96-98].

## 589 **Anxiety and depression levels**

### 590 **The Hospital Anxiety and Depression Scale (HADS)**

591 Several instruments in the scientific literature have been used to assess anxiety  
592 and depression [99] The HADS was created 30 years ago by Zigmond and  
593 Snaith to identify symptoms of anxiety and depression in non-psychiatric  
594 inpatients and later on in outpatients and other types of patients [100]. The  
595 HADS has been validated for use in Brazil by [101], and it is short and takes a  
596 few minutes to complete while waiting for an appointment with the doctor. The  
597 HADS uses a 4-point response scale (0–3) according to the severity of anxiety  
598 and depression. The depression domain was measured using seven items, and  
599 the other seven items measured the anxiety domain. The total score for each  
600 domain ranges from 0 to 21. In both domains, cases with scores from 0 to 7  
601 points were considered normal, cases from 8 to 10 points were considered to  
602 have a borderline abnormality, and scores from 11 to 21 were evaluated as  
603 cases of anxiety or depression depending on the dotted domain.<sup>1</sup>

604 **The Self-Assessment of Anxiety Scale (SAS) and the Self-Assessment of**  
605 **Depression Scale (SDS)**

606 The SAS and SDS are instruments commonly used in the assessment of  
607 negative emotions in clinical practice and are frequently applied to assess the  
608 state of adults with symptoms of anxiety and depression [102].

609 Each scale is composed of 20 items, using a four-level score formulated as  
610 positive (1–4) or negative (4–1). The SAS identifies the presence of affective  
611 symptoms based on diagnostic criteria corrected in the American psychiatric  
612 literature and assesses four dimensions: cognitive, motor, vegetative, and  
613 central nervous system. The total scale score was the sum of the scores for  
614 each item. A score below 50 indicates anxiety, a score of 50–60 indicates level  
615 anxiety, a score of 61–70 indicates moderate anxiety, and a score above 70  
616 indicates severe anxiety.

617 The choice of items on the SDS scale was based on studies of an analytical  
618 factor of depressive symptoms. The cutoff score was 53, indicating that  
619 standard scores greater than 53 induced depression [103]. In Brazil, there has  
620 already been validation for the SAS, which has been used with excellent  
621 reliability [104]. Both scores range from 20 to 80 (raw score), and then these  
622 scores are converted into indices ranging from 25 to 100.

623 **Posttraumatic stress disorder: Impact of Event Scale-6 (IES-6)**

624 The IES-6 is an abbreviated version of the Impact of Event Scale-Revised (IES-  
625 R), which consists of six five-point items, ranging from 0 to 4 [105]. The IES-6 is  
626 an instrument used to identify individuals with significant symptoms of traumatic  
627 stress who need a more extensive evaluation to determine the diagnostic criteria

628 for PTSD, without confirmation of a clinical diagnosis [106]. The IES-6 is a  
629 reliable and valid tool for screening PTSD and survivors of ARDS and is widely  
630 used in hospitalized and discharged patients [107]. This scale has been used in  
631 some studies to assess the prevalence of and risk factors for PTSD in patients  
632 with COVID19 [108].

### 633 **Safety assessment**

634 All patients will be monitored during all pulmonary rehabilitation program  
635 activities. Vital signs, such as temperature, heart rate, partial oxygen saturation,  
636 and peripheral blood pressure, will be evaluated at the beginning, during, and at  
637 the end of each session. Peripheral oxygen saturation and heart rate were  
638 continuously monitored using a G-Tech pulse oximeter (Beijing Choice  
639 Electronics Technology Co., Ltd., Beijing, China). Peripheral blood pressures  
640 will be measured using a clinical Premium aneroid sphygmomanometer  
641 (Wenzhou Instruments Co, China) at the beginning and end of the session or if  
642 the patient shows any pressure discomfort.

643 The perceived exertion by the patients was registered throughout the aerobic  
644 training phase using the Borg Dyspnea Scale. Training will always be  
645 conducted by an experienced physiotherapist, who is a member of the research  
646 team. If the systolic and/or diastolic blood pressure reaches the maximum pre-  
647 established limits, the patient will be instructed to reduce the effort and/or stop  
648 the activity for a few minutes until the pressure stabilizes and returns to normal  
649 values. In view of this clinical situation, the patient was referred to a specialist  
650 physician for clinical re-evaluation.

651

## 652 **Sample size and power calculation**

653 The sample size was calculated according to Shahin et al. (2008). This  
654 calculation is based on the mean difference in the distance covered in the test,  
655 which should be clinically significant. Considering a difference within +8  
656 (control) and +46 (intervention), for a sample size of 35 and 36 patients,  
657 respectively, and an SD within each group of 9.2, an  $\alpha$  error probability of 0, 05,  
658 and a power (1 - error probability  $\beta$ ) of 0.80 for repeated measures, for repeated  
659 measures analysis (between factors), a total sample size of 36 individuals was  
660 needed to reach a power of 81.77%. An additional 10% of subjects were  
661 required to adjust for other factors, such as dropouts, lost data, and loss to  
662 follow-up, which resulted in a total of 40 subjects per group. G\*Power Statistical  
663 Power Analyses for Mac were utilized according to the appropriate reference  
664 [109,110].

## 665 **Statistical analyses**

666 The Kolmogorov–Smirnov test was used to test the normality of the distribution  
667 of the verified variables. For intragroup comparisons, we will use the Student’s  
668 t-test for paired samples that presented parametric distribution or the Mann–  
669 Whitney test for variables whose distribution was non-parametric. Intergroup  
670 comparisons were made using one-way analysis of variance (ANOVA), and  
671 Tukey's post-test was used for paired comparisons whenever the null  
672 hypothesis was rejected by ANOVA. For intergroup comparisons of variables  
673 that presented a non-parametric distribution, we used the Kruskal–Wallis test,  
674 and the paired comparison (when the null hypothesis was rejected) was made  
675 using the Mann–Whitney test. The chi-square test was used to test the

676 association between the groups and exacerbations/hospitalizations. All  
677 analyses will be performed using the Statistical Package for Social Science  
678 (SPSS) version 23.0 (IBM Corp. Released 2015. IBM SPSS Statistics for  
679 Windows, version 23.0. Armonk, NY: IBM Corp). The significance level  
680 established for all analyses was set at 5%.

### 681 **Data management**

682 All clinical data of the patients involved in the study will be collected through  
683 specific standardized forms for clinical evaluation and stored in a database  
684 created by the Scientific Coordination of the Protocol and protected by a  
685 password. All patient identification will be replaced by a code to maintain the  
686 confidentiality of the data collected. At the end of each activity day, the collected  
687 data were backed and exported to another computer. Any changes to the  
688 proposed protocol will be immediately communicated to the institution's  
689 Research Ethics Committee and ClinicalTrials.gov.

### 690 **Strategies of study retention**

691 In the initial phase of protocol evaluation, all patients will participate in a health  
692 education program at the institution, where they will receive information about  
693 the development and progression of the disease, its treatment (both drug and  
694 non-drug), the correct use of oxygen, and the importance of participating in a  
695 pulmonary rehabilitation program. All patients received a booklet containing the  
696 content of the educational program and guidance on the practice of physical  
697 activities. During the study period, participants allocated to the home pulmonary  
698 rehabilitation group will receive weekly phone calls to monitor the activities  
699 performed during the week, check for the presence of adverse events, and

700 encourage and not drop out of the program. Psychological strategies to improve  
701 self-esteem will also be adopted by all patients and their caregivers.

## 702 **Discussion**

703 International scientific literature has demonstrated the effectiveness of  
704 pulmonary rehabilitation in patients with chronic and acute lung diseases. In this  
705 sense, we hope that patients affected by COVID-19 undergoing an outpatient  
706 and home pulmonary rehabilitation program will obtain benefits in the short-,  
707 medium-, and long-term. We highlight the benefits in terms of reduced fatigue  
708 and dyspnea, increased functional and exercise capacity, reduced limitations in  
709 ADLs, improved quality of life, mood and motivation, increased adherence to  
710 recommended clinical treatments, increased participation in therapy decisions,  
711 strengthening the patient's self-management capacity, and reducing the amount  
712 of health care for patients, families, and communities, including reducing the  
713 number of hospitalizations and increasing survival, with a consequent reduction  
714 in health costs for the state.

## 715 **Potential impact and significance of the study**

716 According to the international scientific literature, which shows excellent results  
717 of pulmonary rehabilitation for patients with pulmonary diseases, we expect  
718 that, with the participation of patients affected by COVID-19 in outpatient and  
719 home pulmonary rehabilitation programs, we will obtain benefits in the short,  
720 medium, and long term. The potential clinical impact of this study will be to  
721 reduce fatigue and dyspnea, increase functional and exercise capacity, reduce  
722 limitations in ADLs, improve quality of life, and consequently reduce morbidity  
723 and mortality in patients affected by COVID-19. A reduction in decompensation

724 and hospitalizations is also expected, representing a reduction in health costs  
725 by the government. It is hoped that with the results of this clinical trial, we can  
726 encourage the scientific community to increase the availability of pulmonary  
727 rehabilitation programs for the large number of patients surviving COVID-19,  
728 improve the quality of life, and increase survival.

### 729 **Strengths and weakness of the study**

730 Currently, there are a small number of clinical trial protocols for pulmonary  
731 rehabilitation programs aimed at patients with post-COVID-19 sequelae  
732 according to international clinical trial registry agencies. A strong point of the  
733 research is that patients who cannot access the activities of the outpatient  
734 pulmonary rehabilitation program will be able to perform the same activities at  
735 home. Another strength of this clinical trial is that robust results were not  
736 observed in the scientific literature on the clinical response of post-COVID-19  
737 patients undergoing pulmonary rehabilitation programs. One weakness of this  
738 clinical trial is the fact that it is not controlled; however, it is justified by the fact  
739 that it is unethical to leave patients who present sequelae of COVID-19 without  
740 participating in a rehabilitation program.

### 741 **Dissemination policy**

742 The results of this clinical trial will be shared with potential users and peers in  
743 the field of research, scientific societies, and people formulating public health  
744 policies, thus contributing to the progress of science in general and improving  
745 the population's quality of life. The results of this study will be presented at  
746 scientific conferences and submitted as a manuscript to scientific journals. The  
747 database is made available upon request.



748 **How amendments to the study, including termination, will be dealt with**

749 Any changes in the execution of the proposed initial protocol and/or adverse  
750 events that occur to patients will be communicated to the Research Ethics  
751 Committee of the institution, ClinicalTrials.gov, and the health authorities of our  
752 country.

753 **Acknowledgements**

754 The authors would like to thank Fundação de Amparo a Pesquisa do Estado de  
755 Goiás (FAPEG) and Universidade Evangélica de Goiás (UniEVANGÉLICA) for  
756 their support in all phases of organizing this study protocol.

757

758

759

760 **References**

- 761 1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic.  
762 Acta Biomed. 2020;91(1):157-160.
- 763 2. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E,  
764 Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al.  
765 Clinical, laboratory and imaging features of COVID-19: A  
766 systematic review and meta-analysis. Travel Med Infect Dis.  
767 2020;101623.
- 768 3. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli  
769 A, et al. Baseline Characteristics and Outcomes of 1591 Patients  
770 Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy  
771 Region, Italy. JAMA. 2020;323(16):1574-1581.
- 772 4. Wu Z, McGoogan JM. Characteristics of and Important Lessons  
773 From the Coronavirus Disease 2019 (COVID-19) Outbreak in  
774 China: Summary of a Report of 72 314 Cases From the Chinese

- 775 Center for Disease Control and Prevention. JAMA. 2020;  
776 323(13):1239-1242.
- 777 5. Cheng ZJ, Shan J. Review 2019 Novel coronavirus: where we are  
778 and what we know. Infection. 2020;48(2):155-163.
- 779 6. WHO. Report of the WHO-China joint mission on coronavirus  
780 disease 2019 (COVID-19) WHO; 2020. Feb 16-24, [accessed on  
781 2022 mar 8]. Available at: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf)  
782 [source/coronaviruse/who-china-joint-mission-on-covid-19-final-](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf)  
783 [report.pdf](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf).
- 784 7. Kakodkar P, Kaka N, Baig M. A comprehensive literature review  
785 on the clinical presentation, and management of the pandemic  
786 coronavirus disease 2019 (COVID-19). Cureus. (2020) 12:e7560.
- 787 8. Epidemiology Working Group for NCIP Epidemic Response,  
788 Chinese Center for Disease Control and Prevention. [The  
789 epidemiological characteristics of an outbreak of 2019 novel  
790 coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing  
791 Bing Xue Za Zhi. 2020;41(2):145-151.
- 792 9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T,  
793 Davidson KW. Presenting characteristics, comorbidities, and  
794 outcomes among 5700 patients hospitalized with COVID-19 in the  
795 New York city area. J. Am. Med. Assoc. 2020;323(20):2052–2059.
- 796 10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and  
797 risk factors for mortality of adult inpatients with COVID-19 in  
798 Wuhan, China: a retrospective cohort study. Lancet.  
799 2020;395(10229):1054-1062.
- 800 11. Sanchez-Ramirez DC, Normand K, Zhaoyun Y, Torres-Castro R.  
801 Long-term impact of COVID-19: A systematic review of the  
802 literature and meta-analysis. Biomedicines. 2021;9(8),900.
- 803 12. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-  
804 COVID-19 Syndrome: The Persistent Symptoms at the Post-viral  
805 Stage of the Disease. A Systematic Review of the Current Data.  
806 Front Med (Lausanne). 2021;8:653516.
- 807 13. Sigfrid L, Cevik M, Jesudason E, Lim WS, Rello J, Amuasi J, et al.  
808 What is the recovery rate and risk of long-term consequences

- 809 following a diagnosis of COVID-19? A harmonised, global  
810 longitudinal observational study protocol. *BMJ Open*.  
811 2021;11(3):e043887.
- 812 14. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of  
813 SARS-CoV-2 infection—a review of immune changes in patients  
814 with viral pneumonia. *Emerg Microbes Infect*. 2020;9:727–32.
- 815 15. Darif D, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K.  
816 The pro-inflammatory cytokines in COVID-19 pathogenesis: What  
817 goes wrong? *Microb Pathog*. 2021;153:104799.
- 818 16. Jennings G, Monaghan A, Xue F, Mockler D, Romero-Ortuño R. A  
819 Systematic Review of Persistent Symptoms and Residual  
820 Abnormal Functioning following Acute COVID-19: Ongoing  
821 Symptomatic Phase vs. Post-COVID-19 Syndrome. *J Clin Med*.  
822 2021;10(24):5913.
- 823 17. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R,  
824 Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of  
825 COVID-19: a systematic review and meta-analysis. *Scientific*  
826 *reports*.2021;11(1), 1-12.
- 827 18. Nakanishi N, Liu K, Kawakami D, Kawai Y, Morisawa T, Nishida T,  
828 et al. Post-Intensive Care Syndrome and Its New Challenges in  
829 Coronavirus Disease 2019 (COVID-19) Pandemic: A Review of  
830 Recent Advances and Perspectives. *J Clin Med*.  
831 2021;10(17):3870.
- 832 19. Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R.  
833 Frequency, signs and symptoms, and criteria adopted for long  
834 COVID-19: A systematic review. *International journal of clinical*  
835 *practice*. 2021;75(10)e14357.
- 836 20. Vitacca M, Lazzeri M, Guffanti E, Frigerio P, Gianola S, Carone M,  
837 et al. An Italian consensus on pulmonary rehabilitation in COVID-  
838 19 patients recovering from acute respiratory failure: results of a  
839 Delphi process. *Monaldi Archives for Chest Disease*. 2020;90(2).
- 840 21. Barker-Davies RM, O'Sullivan O, Senaratne KPP, Baker P,  
841 Cranley M, Dharm-Datta S, et al. The Stanford Hall consensus

- 842 statement for post-COVID-19 rehabilitation. *Br J Sports Med.*  
843 2020;54(16):949-959.
- 844 22. Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters  
845 T. COVID-19: Interim Guidance on Rehabilitation in the Hospital  
846 and Post-Hospital Phase from a European Respiratory Society  
847 and American Thoracic Society-coordinated International Task  
848 Force. *Eur Respir J.* 2020.
- 849 23. Zhao HM, Xie YX, Wang C. Chinese Association of Rehabilitation  
850 Medicine; Respiratory Recommendations for respiratory  
851 rehabilitation in adults with coronavirus disease 2019.  
852 Rehabilitation Committee of Chinese Association of Rehabilitation  
853 Medicine; Cardiopulmonary Rehabilitation Group of Chinese  
854 Society of Physical Medicine and Rehabilitation. *Chin Med J*  
855 (Engl). 2020;133(13):1595-1602.
- 856 24. Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, et  
857 al. Updated guidance on the management of COVID-19: from an  
858 American Thoracic Society/European Respiratory Society  
859 coordinated International Task Force (29 July 2020). *Eur Respir*  
860 *Rev.* 2020;29(157):200287.
- 861 25. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C,  
862 et al. ATS/ERS Task Force on Pulmonary Rehabilitation. An  
863 official American Thoracic Society/European Respiratory Society  
864 statement: key concepts and advances in pulmonary  
865 rehabilitation. *Am J Respir Crit Care Med.* 2013;188(8):e13-64.
- 866 26. Gloeckl R, Leitl D, Jarosch I, Schneeberger T, Nell C, Stenzel N,  
867 et al. Benefits of pulmonary rehabilitation in COVID-19: a  
868 prospective observational cohort study. *ERJ Open Res.*  
869 2021;7(2):00108-2021.
- 870 27. Everaerts S, Heyns A, Langer D, Beyens H, Hermans G,  
871 Troosters T, et al. COVID-19 recovery: benefits of multidisciplinary  
872 respiratory rehabilitation. *BMJ Open Respir Res.*  
873 2021;8(1):e000837.
- 874 28. Mohamed AA, Alawna M. Role of increasing the aerobic capacity  
875 on improving the function of immune and respiratory systems in

- 876 patients with coronavirus (COVID-19): a review. *Diabetes Metab*  
877 *Syndr* 2020;14:489–496.
- 878 29. Santana AV, Fontana AD, Pitta F. Pulmonary rehabilitation after  
879 COVID-19. *J Bras Pneumol*. 2021;47(1):e20210034.
- 880 30. Wang TJ, Chau B, Lui M, Lam GT, Lin N, Humbert S. PM&R and  
881 pulmonary rehabilitation for COVID-19. *American journal of*  
882 *physical medicine & rehabilitation*. 2020.
- 883 31. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT  
884 2010 statement: updated guidelines for reporting parallel group  
885 randomized trials. *Ann Intern Med*. 2010;152(11):726-32.
- 886 32. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC,  
887 Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard  
888 protocol items for clinical trials. *Ann Intern Med*. 2013;158(3):200-  
889 7.
- 890 33. American Thoracic Society Statement. Lung function testing:  
891 selection of reference values and interpretative strategies. *Am Rev*  
892 *Respir Dis*.1991;144:1202-18.
- 893 34. Medina-Mirapeix F, Bernabeu-Mora R, Llamazares-Herrán E,  
894 Sánchez-Martínez MP, García-Vidal JA, Escolar-Reina P.  
895 Interobserver Reliability of Peripheral Muscle Strength Tests and  
896 Short Physical Performance Battery in Patients With Chronic  
897 Obstructive Pulmonary Disease: A Prospective Observational  
898 Study. *Arch Phys Med Rehabil*. 2016;97(11):2002-2005.
- 899 35. ATS Committee on Proficiency Standards for Clinical Pulmonary  
900 Function Laboratories. ATS statement: guidelines for the six-  
901 minute walk test. *Am J Respir Crit Care Med*. 2002;166:111-7.
- 902 36. Wedzicha JA, Jones PW. Usefulness of the Medical Research  
903 Council (MRC) dyspnea scale as a measure of disability in  
904 patients with chronic obstructive pulmonary disease.
- 905 37. Saidi I, Koumeke PP, Ait Batahar S, Amro L. Factors associated  
906 with anxiety and depression among patients with Covid-19. *Respir*  
907 *Med*. 2021 Sep;186:106512.
- 908 38. Sociedade Brasileira de Pneumologia e Tisiologia. I Consenso  
909 brasileiro sobre espirometria. *J Pneumol*. 1996;22:105-164.

- 910           39. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS;  
911           GOLD Scientific Committee. Global strategy for the diagnosis,  
912           management, and prevention of chronic obstructive pulmonary  
913           disease. NHLBI/WHO Global Initiative for Chronic Obstructive  
914           Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care*  
915           *Med.* 2001;163(5):1256-76.
- 916           40. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R,  
917           Coates A, et al. ATS/ERS Task Force. Standardisation of  
918           spirometry. *Eur Respir J.* 2005;26(2):319-38.
- 919           41. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper  
920           BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An  
921           Official American Thoracic Society and European Respiratory  
922           Society Technical Statement. *American Journal of Respiratory and*  
923           *Critical Care Medicine.* 2019; 200(8):e70–e88.
- 924           42. Pereira CAC. II Consenso Brasileiro de Espirometria. *J Pneumol*  
925           2002;28(3):S1-S82.
- 926           43. ATS Committee on Proficiency Standards for Clinical Pulmonary  
927           Function Laboratories. ATS statement: guidelines for the six-  
928           minute walk test. *Am J Respir Crit Care Med.* 2002;166(1):111-  
929           117.
- 930           44. Sciruba FC, Slivka WA. Six-minute walk-testing. *Semin Resp Crit*  
931           *Care Med* 1998; 9: 383–391.
- 932           45. ATS Statement: Guidelines for the six-minute walk test. *Am J*  
933           *Respir Crit Care Med* 2002; 166: 111–117.
- 934           46. Enright PL, McBurnie MA, Bittner V, Tracy RP, McNamara R,  
935           Arnold A, Newman AB; Cardiovascular Health Study. The 6-min  
936           walk test: a quick measure of functional status in elderly adults.  
937           *Chest.* 2003;123(2):387-98.
- 938           47. Casanova C, Cote C, de Torres JP, et al. The inspiratory lung  
939           capacity ratio predicts mortality in patients with COPD. *Am J*  
940           *Respir Crit Care Med* 2005; 171: 591–597.
- 941           48. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical  
942           activities in daily life in COPD. *Am J Respir Crit Care Med* 2005;  
943           171:972–977.

- 944 49. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance:  
945 change over time and value as a predictor of survival in severe  
946 COPD. *Eur Respir J* 2004; 23: 28–33.
- 947 50. Casanova C, Cote C, Mari'n JM, et al. Distance and oxygen  
948 desaturation during six minute walk test as predictors of longterm  
949 mortality in patients with COPD. *Chest* 2008; 134: 746–752.
- 950 51. Cote CG, Casanova C, Mari'n JM, et al. Validation and  
951 comparison of reference equations for the six-minute walk test.  
952 *Eur Respir J* 2008; 31: 571–578.
- 953 52. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative  
954 systematic overview of the measurement properties of functional  
955 walk tests used in the cardiorespiratory domain. *Chest*  
956 2001;119:256–270.
- 957 53. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers  
958 D, Kant KM, et al. Confirmation of the high cumulative incidence of  
959 thrombotic complications in critically ill ICU patients with COVID-  
960 19: an updated analysis. *Thromb Res.* 2020;191:148–50.
- 961 54. Klok FA, Barco S, Siegerink B. Measuring functional limitations  
962 after venous thromboembolism: a call to action. *Thromb Res.*  
963 2019;178:59–62.
- 964 55. Boon GJAM, Barco S, Bertoletti L, Ghanima W, Huisman MV,  
965 Kahn SR, et al. Measuring functional limitations after venous  
966 thromboembolism: optimization of the Post-VTE Functional Status  
967 (PVFS) Scale. *Thromb Res.* 2020;190:45–51.
- 968 56. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers  
969 D, Kant KM, et al. Confirmation of the high cumulative incidence of  
970 thrombotic complications in critically ill ICU patients with COVID-  
971 19: an updated analysis. *Thromb Res.* 2020;191:148–50.
- 972 57. Klok FA, Boon GJ, Barco S, Endres M, Geelhoed JM, Knauss S,  
973 et al. The Post-COVID-19 Functional Status scale: a tool to  
974 measure functional status over time after COVID-19. *European*  
975 *Respiratory Journal*; 2020; 56(1).
- 976 58. Machado FV, Meys R, Delbressine JM, Vaes, AW, Goertz YM,  
977 van Herck M, et al. Construct validity of the Post-COVID-19

- 978 Functional Status Scale in adult subjects with COVID-19. Health  
979 and quality of life outcomes.2021;19(1), 1-10.
- 980 59. Schönhofer B, Ardes P, Geibel M, Köhler D, Jones PW. Evaluation  
981 of a movement detector to measure daily activity in patients with  
982 chronic lung disease. *Eur Respir J.* 1997;10(12):2814-9.
- 983 60. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M,  
984 Gosselink R. Characteristics of physical activities in daily life in  
985 chronic obstructive pulmonary disease. *Am J Respir Crit Care*  
986 *Med.* 2005;171(9):972-7.
- 987 61. Lareau SC, Breslin EH, Meek PM. Functional status instruments:  
988 outcome measure in the evaluation of patients with chronic  
989 obstructive pulmonary disease. *Heart Lung.* 1996;25(3):212-24.
- 990 62. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M,  
991 Gosselink R. Physical activity and hospitalization for exacerbation  
992 of COPD. *Chest.* 2006;129(3):536-44.
- 993 63. Pitta F, Troosters t, Probst VS, Lucas S, Decramer M, Gosselink  
994 R. Potential consequences for stable chronic obstructive  
995 pulmonary disease patients who do not get the recommended  
996 minimum daily amount of physical activity. *J Bras Pneumol.*  
997 2006;32(4):301-8.
- 998 64. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM.  
999 Regular physical activity reduces hospital admission and mortality  
1000 in chronic obstructive pulmonary disease: a population based  
1001 cohort study. *Thorax.* 2006;61(9):772-8.
- 1002 65. Lareau SC, Meek PM, Roos PJ. Development and testing of the  
1003 modified version of the pulmonary functional status and dyspnea  
1004 questionnaire (PFSDQ-M). *Heart Lung.* 1998;27(3):159-68.
- 1005 66. 11. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW,  
1006 Wedzicha JA. Usefulness of the Medical Research Council (MRC)  
1007 dyspnoea scale as a measure of disability in patients with chronic  
1008 obstructive pulmonary disease. *Thorax.* 1999;54(7):581-6.
- 1009 67. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha  
1010 JA. Usefulness of the Medical Research Council (MRC) dyspnoea



- 1011 scale as a measure of disability in patients with chronic obstructive  
1012 pulmonary disease. *Thorax*. 1999;54(7):581-6.
- 1013 68. Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta  
1014 F. Validation of the Modified Pulmonary Functional Status and  
1015 Dyspnea Questionnaire and the Medical Research Council scale  
1016 for use in Brazilian patients with chronic obstructive pulmonary  
1017 disease. *Jornal Brasileiro de pneumologia*. 2008;34:1008–18.
- 1018 69. ISARIC. ISARIC Covid-19 long term follow up study Tier 1 Initial  
1019 Survey First Follow Up, Oxford, UK, 2021. [cited 2021 Oct 16].  
1020 Available from: [https://isaric.org/wp-](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follow_up.PT_.pdf)  
1021 [content/uploads/2021/02/ISARIC\\_Global\\_COVID-](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follow_up.PT_.pdf)  
1022 [19\\_Long\\_term\\_Follow\\_up\\_Study\\_Tier\\_1\\_Initial\\_Survey\\_first\\_follo](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follow_up.PT_.pdf)  
1023 [w\\_up.PT\\_.pdf](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follow_up.PT_.pdf)
- 1024 70. ISARIC. ISARIC Covid-19 long term follow up study Tier 1 Initial  
1025 Survey First Follow Up, Oxford, UK, 2021. [cited 2021 Oct 16].  
1026 Available from: [https://isaric.org/wp-](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follow_up.PT_.pdf)  
1027 [content/uploads/2021/02/ISARIC\\_Global\\_COVID-](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follow_up.PT_.pdf)  
1028 [19\\_Long\\_term\\_Follow\\_up\\_Study\\_Tier\\_1\\_Initial\\_Survey\\_first\\_follo](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follow_up.PT_.pdf)  
1029 [w\\_up.PT\\_.pdf](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follow_up.PT_.pdf) [https://isaric.org/wp-](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_Term_Follow_up_Study_Tier_1_ONGOING_Survey.PT_.pdf)  
1030 [content/uploads/2021/02/ISARIC\\_Global\\_COVID-](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_Term_Follow_up_Study_Tier_1_ONGOING_Survey.PT_.pdf)  
1031 [19\\_Long\\_Term\\_Follow\\_up\\_Study\\_Tier\\_1\\_ONGOING\\_Survey.PT](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_Term_Follow_up_Study_Tier_1_ONGOING_Survey.PT_.pdf)  
1032 [\\_.pdf](https://isaric.org/wp-content/uploads/2021/02/ISARIC_Global_COVID-19_Long_Term_Follow_up_Study_Tier_1_ONGOING_Survey.PT_.pdf)
- 1033 71. ISARIC. ISARIC Covid-19 long term follow up study Oxford, UK,  
1034 2021. [cited 2021 Oct 16]. Available from: Available from:  
1035 [https://isaric.org/research/covid-19-clinical-research-](https://isaric.org/research/covid-19-clinical-research-resources/follow-up-forms-surveys/)  
1036 [resources/follow-up-forms-surveys/](https://isaric.org/research/covid-19-clinical-research-resources/follow-up-forms-surveys/)
- 1037 72. American Thoracic Society/European Respiratory Society.  
1038 ATS/ERS Statement on respiratory muscle testing. *Am J Respir*  
1039 *Crit Care Med*. 2002;166(4):518-624.
- 1040 73. Pessoa IM, Hourí Neto M, Montemezzo D, Silva LA, Andrade AD,  
1041 Parreira VF. Predictive equations for respiratory muscle strength  
1042 according to international and Brazilian guidelines. *Braz J Phys*  
1043 *Ther*. 2014;18(5):410-8.

- 1044 74. Fess FE. Grip strength. Casanova JS clinical assessment  
1045 recommendations (2nd ed.). American society of hand therapists.  
1046 1992;41–5.
- 1047 75. Boadella JM, Kuijer PP, Sluiter JK, Frings-Dresen MH. Effect of  
1048 self-selected handgrip position on maximal handgrip strength.  
1049 Arch Phys Med Rehabil. 2005;86(2):328-31.
- 1050 76. Watanabe T, Owashi K, Kanauchi Y, Mura N, Takahara M, Ogino  
1051 T. The short-term reliability of grip strength measurement and the  
1052 effects of posture and grip span. The Journal of hand surgery.  
1053 2005;30(3):603–9.
- 1054 77. Luna-Heredia E, Martín-Peña G, Ruiz-Galiana J. Handgrip  
1055 dynamometry in healthy adults. Clinical Nutrition. 2005;24(2):250–  
1056 8.
- 1057 78. Roberts HC, Denison HJ, Martin HJ, et al. A review of the  
1058 measurement of grip strength in clinical and epidemiological  
1059 studies: towards a standardised approach. Age Ageing.  
1060 2011;40:423–429.
- 1061 79. Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver  
1062 agreement in the assessment of muscle strength and functional  
1063 abilities in Guillain-Barré syndrome. Muscle Nerve. 1991;17:1103–  
1064 1109.
- 1065 80. Ciesla N, Dinglas V, Fan E, Kho M, Kuramoto J, Needham D.  
1066 Manual muscle testing: a method of measuring extremity muscle  
1067 strength applied to critically ill patients. J Vis Exp 2011;  
1068 12(50):2632.
- 1069 81. Parry SM, Berney S, Granger CL, Dunlop DL, Murphy L, El-Ansary  
1070 D, et al. A new two-tier strength assessment approach to the  
1071 diagnosis of weakness in intensive care: an observational study.  
1072 Critical Care. 2015;19(1):1–10.
- 1073 82. Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM,  
1074 de Jonghe B, Ali NA, Sharshar T. A framework for diagnosing and  
1075 classifying intensive care unit-acquired weakness. Crit Care Med.  
1076 2009;17:S299–S308.

- 1077 83. Miyamoto, S. T., Lombardi Júnior, I., Berg, K. O., Ramos, L. R., &  
1078 Natour, J. Brazilian version of the Berg balance scale. Brazilian  
1079 journal of medical and biological research. 2004;37(9):1411-1421.
- 1080 84. Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic  
1081 functional mobility for frail elderly persons. J Am Geriatr  
1082 Soc.1991;39:142–148.
- 1083 85. Mesquita R, Wilke S, Smid DE, Janssen DJA, Franssen FME,  
1084 Probst VS, et al. Measurement properties of the Timed Up & Go  
1085 test in patients with COPD. Chron Respir Dis. 2016;13(4):344–52.
- 1086 86. Delbressine JM, Vaes AW, Goe“rtz YM, Sillen MJ, Kawagoshi A,  
1087 Meijer K, et al. Effects of ExerciseBased Interventions on Fall Risk  
1088 and Balance in Patients With Chronic Obstructive Pulmonary  
1089 Disease: A systematic review. J Cardiopulm Rehabil Prev. 2020;  
1090 40(3):152–63.
- 1091 87. Rogind, H., Simonsen, H., Era, P., & Bliddal, H. Comparison of  
1092 Kistler 9861A force platform and Chattecx Balance System® for  
1093 measurement of postural sway: correlation and test–retest  
1094 reliability. Scandinavian journal of medicine & science in sports.  
1095 2003;13(2):106-114.
- 1096 88. Gimenez FV, Stadnik AMW, Maldaner M. Analyses of  
1097 Baropodometry Protocols Through Bibliometric Research. Annu  
1098 Int Conf IEEE Eng Med Biol Soc. 2018;2018:3882-3885.
- 1099 89. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue  
1100 severity scale: application to patients with multiple sclerosis and  
1101 systemic lupus erythematosus. Archives of neurology.  
1102 1989;46(10):1121–3.
- 1103 90. Krupp LB, Pollina DA. Mechanisms and management of fatigue in  
1104 progressive neurological disorders. Curr Opin Neurol 1996;9:456-  
1105 460.
- 1106 91. Van de Port IG, Kwakkel G, Schepers VP, Heinemans CT,  
1107 Lindeman E. Is fatigue an independent factor associated with  
1108 activities of daily living, instrumental activities of daily living and  
1109 health-related quality of life in chronic stroke? Cerebrovasc Dis.  
1110 2007;23:40–45.

- 1111 92. Valderramas S, Feres AC, Melo A. Reliability and validity study of  
1112 a Brazilian-Portuguese version of the fatigue severity scale in  
1113 Parkinson's disease patients. *Arquivos de neuro-psiquiatria*.  
1114 2012;70:497–500.
- 1115 93. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health  
1116 survey (SF-36): I. Conceptual framework and item selection.  
1117 *Medical care*. 1992;473–83.
- 1118 94. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR.  
1119 Tradução para a língua portuguesa e validação do questionário  
1120 genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36).  
1121 *Rev bras reumatol*. 1999;39(3):143–50.
- 1122 95. Temperoni C, Grieco S, Pasquini Z, Canovari B, Polenta A, Gnudi  
1123 U, et al. Clinical characteristics, management and health related  
1124 quality of life in young to middle age adults with COVID-19. *BMC*  
1125 *Infectious Diseases*. 2021;21(1):1–10.
- 1126 96. EQ-5D [Internet]. [cited 2021 Oct 22. Available from:  
1127 <https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/>
- 1128 97. EQ-5D-5L. User Guide Basic information on how to use the EQ-  
1129 5D-5L instrument. [Internet]. [cited 2021 Oct 22. Available from:  
1130 [https://www.unmc.edu/centric/\\_documents/EQ-5D-5L.pdf](https://www.unmc.edu/centric/_documents/EQ-5D-5L.pdf)
- 1131 98. Van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J,  
1132 Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the  
1133 EQ-5D-5L to EQ-5D-3L value sets. *Value in health*.  
1134 2012;15(5):708–15.
- 1135 99. Alamri HS, Mousa WF, Algarni A, Megahid SF, Al Bshabshe A,  
1136 Alshehri NN, et al. Mental Health of COVID-19 Patients-A Cross-  
1137 Sectional Survey in Saudi Arabia. *Int J Environ Res Public Health*.  
1138 2021 Apr 29;18(9):4758.
- 1139 100. Zigmond AS, Snaith RP. The hospital anxiety and depression  
1140 scale. *Acta psychiatrica scandinavica*. 1983;67(6):361–70.
- 1141 101. Botega NJ, Bio MR, Zomignani MA, Garcia Jr C, Pereira WA.  
1142 Transtornos do humor em enfermaria de clínica médica e  
1143 validação de escala de medida (HAD) de ansiedade e depressão.  
1144 *Revista de saude publica*. 1995;29:359–63.

- 1145 102. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry.  
1146 1965;12:63–70.
- 1147 103. Zung WWK. A rating instrument for anxiety disorders.  
1148 Psychosomatics. 1971;12:371–379.
- 1149 104. Chagas MHN, Tumas V, Loureiro SR, Hallak JE, Trzesniak C, De  
1150 Sousa JPM, et al. Validity of a Brazilian version of the Zung self-  
1151 rating depression scale for screening of depression in patients with  
1152 Parkinson’s disease. Parkinsonism & related disorders. 2010;16(1)
- 1153 105. Weiss DS. The impact of event scale - revised. In: Wilson JP,  
1154 Keane TM, editors. Assessing psychological trauma and PTSD: a  
1155 practitioner’s handbook. New York: Guilford Press. 2004;168–89.
- 1156 106. Thoresen S, Tambs K, Hussain A, Heir T, Johansen VA, Bisson JI.  
1157 Brief measure of posttraumatic stress reactions: Impact of Event  
1158 Scale-6. Social psychiatry and psychiatric epidemiology.  
1159 2010;45(3):405–12.
- 1160 107. Hosey MM, Leoutsakos J-MS, Li X, Dinglas VD, Bienvenu OJ,  
1161 Parker AM, et al. Screening for posttraumatic stress disorder in  
1162 ARDS survivors: validation of the Impact of Event Scale-6 (IES-6).  
1163 Critical Care. 2019;23(1):1–7.
- 1164 108. Vlaker JH, Wesselius S, van Genderen ME, van Bommel J,  
1165 Boxma-de Klerk B, Wils EJ. Psychological distress and health-  
1166 related quality of life in patients after hospitalization during the  
1167 COVID-19 pandemic: A single-center, observational study. PLoS  
1168 One. 2021;16(8):e0255774.
- 1169 109. Shahin B, Germain M, Pastene G, Viallet N and Annat G.  
1170 Outpatient pulmonary rehabilitation in patients with chronic  
1171 obstructive pulmonary disease. 2008;3(1):155-162.
- 1172 110. Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible  
1173 statistical power analysis program for the social, behavioral, and  
1174 biomedical sciences. Behav Res Methods. 2007;39(2):175-91.

1175


1176

	STUDY PERIOD			
	Enrolment	Allocation	Post-allocation	Close-out
<b>TIMEPOINT (weeks)</b>	<b>-1</b>	<b>0</b>	<b>1-6</b>	<b>7</b>
<b>ENROLMENT:</b>				
Eligibility screen	X			
Informed consent	X			
Anthropometric measure				
Allocation		X		
<b>INTERVENTIONS:</b>				
Three times per weeks of Outpatient Pulmonary Rehabilitation Program combination of aerobic (bicycle/treadmill) and muscle strengthening exercises			X	
Three times per weeks of Home PRP combination of aerobic (walking) and muscle strengthening exercises			X	
<b>ASSESSMENTS:</b>				
<b>Primary outcomes</b>				
Pulmonary Function		X		X
Exercise Capacity		X		X
Status Funcional		X		X
Severity of Dyspnea		X		X
<b>Secondary outcomes</b>				
Data on physical and psychosocial health and pre-COVID-19 baseline data		X		X
Maximal Inspiratory Pressure		X		X
Sympathetic and Parasympathetic Autonomic Activity		X		X
Peripheral Muscle Strength		X		X
Static Balance Assessment		X		X
Functional Balance Assessment		X		X
Functional Mobility		X		X

medRxiv preprint doi: <https://doi.org/10.1101/2022.04.08.22273608>; this version posted April 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Muscle Fatigue		X		X
Quality of Life		X		X
Anxiety and Depression Levels		X		X
Posttraumatic Stress Disorder		X		X

medRxiv preprint doi: <https://doi.org/10.1101/2022.04.08.22273608>; this version posted April 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**Figure 2.** Study flowchart in accordance with the CONSORT statement.